周四（12月4日），港股、A股中国科技资产集体回升，港股表现相对亮眼。此前，外资机构扎堆唱多 中国科技。 港股盘面上，芯片产业链携手走强，全市场首只聚焦"港股芯片"的港股信息技术ETF（159131）放量大 涨2.41%；港股AI核心工具——港股互联网ETF（513770）、创新药含量100%的港股通创新药ETF （520880）场内放量携手涨超1%。 | 序号 代码 | | 类型 名称 | 现价 | 涨跌幅 ▼ | 成交额 | | --- | --- | --- | --- | --- | --- | | 1 | 159131 | 跨 港股信息技术ETF T+0 | 0.933 | 2.41% | 9050.34万 | | 2 | 513770 | 跨 港股互联网ETF T+0 | 0.547 | 1.11% | 6.31亿 | | 3 | 520880 | 跨 港股通创新药ETF T+0 | 0.558 | 1.09% | 2.48亿 | | 4 | 520560 | 跨 香港大盘30ETF T+0 | 0.948 | 0.53% | 3904.73万 | | 55 | 159220 | 跨 港股通红利E ...

Core Insights - The Hong Kong and A-share innovative drug sectors have shown significant weekly performance, with notable increases in specific stocks such as Haiwang Bio and Kangfang Biotech, indicating a positive trend in the market [2][4][5]. Market Performance - The pharmaceutical and biotechnology index rose by 1.50%, outperforming the Shanghai Composite Index by 0.10 percentage points, marking two consecutive weeks of gains [4]. - The innovative drug sector (BK1106) saw a weekly increase of 4.26%, while the Hang Seng Healthcare Index (HSCICH) rose by 3.64% and the Hong Kong innovative drug ETF (513120) increased by 4.00% [4]. Stock Highlights - Haiwang Bio experienced a remarkable weekly increase of 38.21%, while Kangfang Biotech led with a 14.86% rise [2]. - The focus on children's antiviral drugs is highlighted by the initiation of Phase III trials for the drug Anladiwei by Zhongsheng Pharmaceutical, targeting a critical market need [12][13]. IPO Developments - Lingke Pharmaceutical has filed for an IPO in Hong Kong, focusing on innovative drugs for autoimmune and inflammatory diseases, with its lead candidate LNK01001 facing intense competition from existing JAK inhibitors [6][7]. - The company reported R&D expenditures of approximately 186 million yuan, 223 million yuan, and 121 million yuan for the years 2023, 2024, and the first nine months of 2025, respectively [7]. Clinical Trials - A total of 110 clinical trial registrations were disclosed by the National Medical Products Administration, with 39 trials in Phase II or higher, indicating robust activity in drug development [8]. - The ongoing clinical trials for various drugs, including SKB500 for small cell lung cancer and Anladiwei for pediatric influenza, reflect the industry's focus on addressing unmet medical needs [14][12]. Regulatory Approvals - Four innovative drugs received approval during the week, including Yimazhi for pediatric Tourette syndrome and a radiopharmaceutical for prostate cancer detection [11]. - The approval of Anladiwei for adult treatment earlier this year and its subsequent pediatric trial initiation underscores the strategic expansion of product lines to meet market demands [13].

Group 1 - The core viewpoint of the article highlights a significant rebound in Chinese technology assets in both Hong Kong and A-shares, with foreign institutions increasingly optimistic about the sector [1][26][30] - The Hong Kong market saw a strong performance in the chip industry chain, with the first ETF focused on "Hong Kong chips" (159131) surging by 2.41% and significant trading volume [1][27][30] - A-shares also showed strength, particularly in the dual innovation sector, with notable gains in semiconductor chips and related ETFs [2][29] Group 2 - Major foreign investment banks, including UBS, Goldman Sachs, and Morgan Stanley, have recently published reports expressing bullish views on Chinese technology stocks, indicating a marked shift in sentiment [3][30] - The AI narrative is driving the market, with companies like Xiaomi making significant advancements in AI applications, further boosting investor confidence [13][14] - The valuation of Hong Kong technology stocks appears attractive, with the Hong Kong Information Technology ETF (159131) trading at a price-to-earnings ratio of 33.75, suggesting substantial upside potential compared to other major indices [7][30] Group 3 - The domestic chip sector is experiencing rapid growth, with sales of domestic AI chips expected to increase from $6 billion last year to $16 billion, reflecting a market share rise from 29% to 42% [6][30] - The Hong Kong Internet ETF (513770) and the Hong Kong Innovation Drug ETF (520880) also saw gains of over 1%, indicating a broader recovery in technology-related assets [1][27][30] - The Hong Kong Innovation Drug ETF (520880) has shown signs of recovery after a significant pullback, with a trading volume of 2.48 billion and a 1.09% increase [18][20][30]

Core Viewpoint - The Hong Kong innovative drug sector has shown signs of recovery after a period of decline, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising by 1.09% on December 4, ending a four-day losing streak and indicating a significant rebound in market sentiment [1][8]. Market Performance - The Hong Kong innovative drug sector has been in a phase of adjustment since early September, with the Hong Kong Stock Connect Innovative Drug ETF (520880) index experiencing a decline of nearly 16% from its previous high, suggesting that prior high-risk levels have been adequately released [3][11]. - The ETF's trading volume reached 248 million yuan, reflecting increased market activity and interest in the sector [1][8]. Positive News Factors - Two major positive developments have been reported: the launch of the Chinese drug price registration system on December 2, which provides market price references for drug imports and exports, and the anticipated release of the new basic medical insurance drug list and the first commercial insurance innovative drug list by the end of the week, which could optimize the payment structure for innovative drug companies [3][11]. Investment Outlook - Short-term forecasts from CITIC Securities suggest that innovative drugs are expected to be a primary upward trend in the market heading into 2026, supported by a robust domestic demand base and comprehensive manufacturing capabilities within the pharmaceutical industry [5][13]. - The current market conditions may present a favorable opportunity for medium to long-term investments in core innovative drug assets, as the sector is entering a critical phase of "innovation realization and global layout" [5][11]. ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) is noted for its significant concentration in leading stocks, with the top ten holdings accounting for 72.57% of the index, indicating a strong representation of core innovative drug companies [6][14]. - The ETF is characterized by its focus on pure innovative drug companies, excluding CXO firms, and aims to provide comprehensive coverage of the innovative drug development sector [5][13].

Core Viewpoint - The Hong Kong stock market, particularly the innovative drug sector, is experiencing a significant rally, with institutions optimistic about the market's future trajectory despite previous adjustments, indicating a continuation of the long-term bull market [1][6][7]. Summary by Sections Innovative Drug Sector Performance - On December 4, the innovative drug sector in Hong Kong saw substantial gains, with companies like Gilead Sciences rising over 11%, and WuXi Biologics and WuXi AppTec increasing by over 7% [2]. - Other notable performers included companies like InnoCare Pharma and BeiGene, which also experienced significant increases [2]. Strategic Developments - WuXi Biologics announced a strategic cooperation memorandum with the Qatar Free Zone Authority, aiming to establish an integrated CRDMO center in the Middle East [4]. - According to research from CMB International, the overall orders and performance in the CXO sector are expected to recover significantly by 2025, driven by improved financing conditions and an increase in overseas demand [4]. Market Outlook and Analyst Recommendations - Analysts from Ping An Securities highlighted the optimization of the medical insurance fund structure and policies encouraging high-quality innovative drug development, suggesting a focus on companies with leading technological platforms in the CXO field [5]. - Nomura reiterated a "buy" rating for WuXi AppTec, raising its target price from HKD 130.63 to HKD 132.8, citing the company's strong R&D capabilities and significant project backlog [5]. - As of September 2025, WuXi Biologics has secured 3,430 projects, three times the number from 2021, with total order backlog reaching CNY 59.88 billion, and new orders increasing by 32% year-on-year [5]. Broader Market Trends - The Hong Kong stock market indices, including the Hang Seng Index and Hang Seng Tech Index, showed positive movements, with gains of 0.68% and 1.45% respectively on December 4 [6]. - Analysts predict a shift in investment logic from traditional valuation recovery to a revaluation based on new productivity and high-quality development, with expectations for moderate expansion in valuation and earnings in 2026 [6]. - The market is anticipated to benefit from internal catalysts and external economic policies, with a forecast for a second round of valuation recovery and further performance improvement in 2026 [7].

Market Performance - The Hong Kong stock market saw a rise on December 4, with the Hang Seng Tech Index increasing by 1.45% to above 5600 points, while the Hang Seng Index rose by 0.68% to 25935 points, and the National Enterprises Index increased by 0.86% to 9106 points [1] - Major tech stocks contributed to the market's upward movement, with Xiaomi rising over 4%, Meituan increasing over 2%, and Tencent, Alibaba, and Baidu also showing gains [1] Sector Highlights - The pharmaceutical sector showed strong performance, particularly in innovative drugs, with companies like Genscript Biotech rising over 11% and WuXi AppTec and WuXi Biologics both increasing over 7% [2] - Semiconductor stocks were active, with SMIC and Hua Hong Semiconductor both rising over 3%. There are market expectations that Cambricon plans to triple its AI chip production by 2026 [2] Commodity Insights - The market for non-ferrous metals, including gold, copper, and aluminum, experienced a mixed performance, with China Nonferrous Mining falling over 4% and Shandong Gold dropping over 3% [4] - International copper prices reached a historical high, with international copper rising nearly 3% and Shanghai copper and tin both increasing over 2% [4] Copper Market Analysis - Goldman Sachs issued a warning regarding the sustainability of rising copper prices, predicting that prices could stabilize between $10,000 and $11,000 per ton by 2026, with a projected surplus of about 500,000 tons this year [6] - The tight supply situation is a key driver for rising copper prices, supported by expectations of reduced smelting output and a favorable downstream operating rate [5][6]

Market Overview - The Hong Kong stock market showed a rebound in the morning session, with the Hang Seng Index closing up 0.68% at 25,935.9 points and a total turnover of HKD 179.3 billion [1] - The Hang Seng China Enterprises Index rose 0.86% to 9,106.48 points, while the Hang Seng Tech Index also saw gains [1] Blue-Chip Stocks Performance - Xiaomi Group-W (01810) performed notably, closing up 4.38% at HKD 41.98, contributing 50.27 points to the Hang Seng Index. The company announced over 500,000 vehicle deliveries since April 2024 and has repurchased 27 million shares for a total of HKD 1.093 billion [2] - Other blue-chip stocks included Trip.com Group-S (09961) up 3.93%, Geely Automobile (00175) up 3.14%, and Meituan-W (03690) up 2.29%. However, Shenzhou International (02313) fell 4.71%, negatively impacting the index [2] Sector Highlights - The CRO and innovative drug sectors saw significant gains, with WuXi Biologics (02269) up 7.09% and WuXi AppTec (02359) up 5.44%. The pharmaceutical industry is expected to experience a pivotal shift by 2025, with a stable outlook continuing into 2026 [3][4] - Robotics stocks surged due to favorable news, with companies like Siasun Robot & Automation (02050) rising 7.7%. The U.S. government is reportedly accelerating the development of robotics technology, which is projected to see exponential growth by 2026 [4] - Gold stocks faced downward pressure, with Shandong Gold (01787) down 3.21% amid concerns over potential gold sales by the Italian government [5] Notable Stock Movements - Auda Holdings (09929) saw a dramatic increase of 370.87% after announcing a major share sale, closing at HKD 0.485 [7] - OSL Group (00863) rose 9.48% after announcing plans to offer compliant digital asset trading services in Europe by Q1 2026 [8] - Cao Cao Travel (02643) increased by 8.33% following the announcement of its Robotaxi strategy, aiming for significant expansion in urban transportation [9] - Longpan Technology (02465) experienced a decline of 7.8% after a previous rise, despite securing a long-term sales agreement for lithium iron phosphate materials [10]

Core Viewpoint - The Hong Kong stock market is experiencing a rebound, with significant strength in sectors such as robotics, innovative pharmaceuticals, and the internet, supported by continuous net inflows from southbound funds, reaching a record high this year [1] Group 1: Market Performance - The Hang Seng Technology Index rose by 1.7% as of 15:07, indicating a positive market sentiment [1] - Southbound funds have recorded net inflows for 29 consecutive weeks, totaling nearly 1.4 trillion HKD this year, marking the highest since the launch of the mutual market access mechanism [1] Group 2: Sector Analysis - Everbright Securities highlights the strong overall profitability of the Hong Kong stock market, with relatively scarce assets in internet, new consumption, and innovative pharmaceuticals, suggesting low valuations and high long-term allocation cost-effectiveness [1] - The Hang Seng Technology Index consists of the 30 largest stocks related to technology themes, focusing on high-growth areas such as artificial intelligence, robotics, and the internet, aiming for "soft and hard synergy" in AI [1] Group 3: Investment Strategies - Investors looking for opportunities in the Hong Kong stock market are encouraged to consider the "dumbbell" strategy, focusing on technology growth and high-dividend sectors, including self-controllable technologies, chips, high-end manufacturing, telecommunications, and public utilities [1] - The Hang Seng High Dividend Low Volatility Index, comprising 50 liquid stocks with consistent dividends and moderate payout ratios, currently has a dividend yield of 6.5%, with energy, finance, and public utilities accounting for over half of the index [1] - Recommended investment products include the E Fund Hang Seng Technology ETF (513010) and the Hang Seng Low Dividend ETF (159545) to construct a balanced investment strategy [1]

Core Viewpoint - The Hong Kong stock market shows signs of recovery after initial declines, with major indices experiencing gains, indicating a potential stabilization in market conditions [1] Market Performance - The Hang Seng Technology Index rose over 1.1% at one point, closing up 0.58%, while the Hang Seng Index and the Hang Seng China Enterprises Index increased by 0.19% and 0.38% respectively [1] - Large technology stocks exhibited mixed performance, with significant gains in robotics and pharmaceutical sectors, particularly in innovative drug concepts [1] Investment Trends - Huatai Securities suggests that the market may be nearing a "bad news fully priced in" state, as core risk factors such as trade tensions and the impact of the "takeaway war" on internet sector profitability have been sufficiently released [1] - Ping An Securities notes that southbound capital continues to flow in, with a net inflow of HKD 121.9 billion in November through the Stock Connect program [1] - Low valuation and high dividend sectors remain attractive for investment in the Hong Kong market, with a focus on technology self-reliance as a key theme for future growth [1] Notable Investment Targets - Core broad-based Hong Kong stock: Hang Seng ETF (159920) [1] - AI and platform economy: Hang Seng Technology Index ETF (513180) [1] - Focus on the development of Chinese enterprises in Hong Kong: Hang Seng China Enterprises ETF (159850) [1]

每日经济新闻 （责任编辑：董萍萍 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 中邮证券指出，医药生物板块2025年初至今震荡上行，短暂回调后性价比凸显，目前估值处于历史 中位，随着集采、院内反腐等负面因素出清，2026年有望表现突出。创新药领域，国内资产全球认可度 快速提升，MNC专利悬崖迫近，新品迭代需求强烈，美国药价政策频出利好国产新药出海；医保商保 协同发力下国产新药商业化前景优异。医疗器械板块部分企业25年三季度业绩迎来拐点，设备板块招投 标持续恢复，有望兑现至2026年业绩；耗材集采逐渐进入尾声，IVD板块在集采冲击下行业整合提速， 负面影响即将出清，整体看器械板块拐点初现，看好后续增长。 创业板医药ETF国泰（159377）跟踪的是创医药指数（399275），单日涨跌幅达20%，该指数聚焦 于创新生物医药领域，从市场中选取涉及生物技术、基因工程、新型疫苗及药物研发等业务的上市公司 证券 ...